STOCK TITAN
  1. Home
  2. News
  3. FHTX

Foghorn Therapeutics Inc. - FHTX STOCK NEWS

Welcome to our dedicated page for Foghorn Therapeutics news (Ticker: FHTX), a resource for investors and traders seeking the latest updates and insights on Foghorn Therapeutics stock.

Foghorn Therapeutics Inc. (FHTX) is a clinical-stage biopharmaceutical pioneer developing precision medicines targeting chromatin regulation in oncology. This news hub provides investors and industry professionals with essential updates on the company's therapeutic pipeline, strategic collaborations, and clinical milestones.

Access timely reports on FHTX's innovative programs including FHD-286 (hematologic cancers), FHD-609 (synovial sarcoma), and FHD-909 (non-small cell lung cancer). Stay informed about regulatory developments, partnership announcements, and scientific presentations related to their Gene Traffic Control platform.

Our curated news collection serves as a comprehensive resource for tracking progress across preclinical studies, clinical trials, and business operations. Bookmark this centralized source for verified updates on Foghorn's novel protein degraders and chromatin-targeting therapies.

News

Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909

Rhea-AI Summary
Foghorn Therapeutics Inc. announces the presentation of preclinical data for its pipeline programs at the 2024 AACR Annual Meeting, including FHD-909, a potential first-in-class BRM selective inhibitor. The data showcases significant progress in developing novel medicines targeting the chromatin regulatory system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.26%
Tags
conferences clinical trial
-
News

Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference

Rhea-AI Summary
Foghorn Therapeutics Inc. (Nasdaq: FHTX) to participate in Cowen’s 44th Annual Health Care Conference, showcasing its Gene Traffic Control® platform in oncology with potential to impact various diseases. The company's Chief Medical Officer will present on March 4, 2024, at 12:50 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.06%
Tags
conferences
-
News

Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor

Rhea-AI Summary
Foghorn® Therapeutics Inc. (Nasdaq: FHTX) announced that Lilly has selected FHD-909, a first-in-class oral BRM selective inhibitor, for clinical development targeting BRG1 mutated non-small cell lung cancer. This collaboration is part of a strategic agreement with Lilly for the development of novel oncology medicines and includes a 50/50 co-development and co-commercialization agreement for Foghorn’s Selective BRM oncology program and an additional undisclosed oncology target.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
55.45%
Tags
none
News

Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024

Rhea-AI Summary
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announces strategic objectives for 2024, including progress in AML combination study, preclinical data for FHD-286 and tyrosine kinase inhibitors, partnership with Loxo@Lilly, and IND filings. The company holds $259.9 million in cash, cash equivalents, and marketable securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.38%
Tags
none
-
News

Foghorn Therapeutics Announces CFO Departure

Rhea-AI Summary
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced the departure of Chief Financial Officer, Allan Reine, to pursue another opportunity. The company is now searching for a successor. Dr. Reine's last day will be January 16, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.82%
Tags
none
-
News

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting

Rhea-AI Summary
Foghorn® Therapeutics Inc. (Nasdaq: FHTX) to present clinical data from Phase 1 dose escalation study of FHD-286 in AML and MDS at ASH Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.65%
Tags
clinical trial
News

Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update

Rhea-AI Summary
Foghorn Therapeutics provides financial and corporate update, with a focus on the FHD-286 combination study in AML. The company presented preclinical data for its Selective EP300 and Selective CBP programs. It also announced a cash runway into the first half of 2026 and a collaboration with Loxo@Lilly. Collaboration revenue increased, while research and development expenses decreased.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.07%
Tags
earnings
-
News

Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs

Rhea-AI Summary
Foghorn Therapeutics will present new data from its preclinical and clinical programs at the 6th Annual Targeted Protein Degradation Summit and the Connective Tissue Oncology Society Annual Meeting. The presentations will cover advancements in degraders targeting key chromatin regulators involved in disease/oncology and preliminary results from a Phase 1 study of FHD-609 in patients with advanced synovial sarcoma or SMARCB1-loss tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
conferences clinical trial
-
News

Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress

Rhea-AI Summary
Foghorn Therapeutics to present clinical data on FHD-286 at ESMO Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
clinical trial
News

Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference

Rhea-AI Summary
Foghorn Therapeutics announces new clinical and pre-clinical data for its inhibitors FHD-286 and FHD-609 to be presented at AACR-NCI-EORTC International Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
conferences clinical trial
Stock FHTX logo
Foghorn Therapeutics Inc.

Nasdaq:FHTX

FHTX Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

FHTX Stock Data

211.33M
45.00M
18.98%
72.61%
1.81%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE